Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2012
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.
Product Name : Carnitor-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
Details : ANI’s Levocarnitine Tablets are the generic version of the Reference Listed Drug (RLD) Carnitor®. The launch of Levocarnitine Tablets is another example of ANI’s commitment to increasing patient access to affordable, high-quality medicines.
Product Name : Levocarnitine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Levocarnitine,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase,Levocarnitine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Peg L asparaginase,Levocarnitine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirfostin,Levocarnitine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Tirfostin,Levocarnitine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine,Selenium
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyperthyroidism: Methimazole Plus L-carnitine and Selenium
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Levocarnitine,Selenium
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icodextrin,Ribitol,Levocarnitine
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : Icodextrin,Ribitol,Levocarnitine
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ribitol,Glucose,Levocarnitine
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
June 27, 2019
Lead Product(s) : Ribitol,Glucose,Levocarnitine
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polydextrin,Levocarnitine,Ribitol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Peritoneal Ultrafiltration in Cardio Renal Syndrome.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 21, 2019
Lead Product(s) : Polydextrin,Levocarnitine,Ribitol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Instituto Nacional de Salud Publica, Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2018
Lead Product(s) : Levocarnitine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Instituto Nacional de Salud Publica, Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable